Gossamer Bio获得Wedbush的“跑赢大盘”评级，目标价为4.00美元。 Gossamer Bio receives an "Outperform" rating from Wedbush with a $4.00 price target.
临床阶段生物制药公司Gossamer Bio获得Wedbush的“跑赢大盘”评级，目标价为4.00美元。 Gossamer Bio, a clinical-stage biopharmaceutical firm, has received an "Outperform" rating from Wedbush with a $4.00 price target. 戈萨默生物正在开发用于肺动脉高血压的seralutinib和用于治疗PAH的GB002在第三阶段试验中. Gossamer Bio is developing seralutinib for pulmonary arterial hypertension and GB002 for PAH treatment in Phase 3 trials. 该公司的“Buy”评级一致,平均目标价格为9.20美元,对机构投资者有很大兴趣。 The company has a consensus "Buy" rating and a $9.20 average target price, with significant institutional investor interest. 分析员的Q3 2024问题每股收入估计数从每股0.17美元到0.23美元不等。 Analysts' Q3 2024 earnings per share estimates range from ($0.17) to ($0.23) per share.